Aratana Therapeutics Inc (NASDAQ:PETX) Receives Average Rating of “Hold” from Analysts

Shares of Aratana Therapeutics Inc (NASDAQ:PETX) have been assigned an average rating of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $4.73.

Several equities analysts have recently issued reports on the stock. BidaskClub lowered shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, July 6th. Zacks Investment Research raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 10th. Credit Suisse Group lowered shares of Aratana Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.76 price target for the company. in a report on Tuesday, April 30th. Finally, HC Wainwright lowered shares of Aratana Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 price target for the company. in a report on Friday, April 26th.

Shares of PETX stock remained flat at $$4.92 on Friday. Aratana Therapeutics has a fifty-two week low of $3.30 and a fifty-two week high of $7.16. The firm has a market capitalization of $241.08 million, a price-to-earnings ratio of -15.38 and a beta of 1.40. The firm has a 50-day moving average of $5.00.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.04). Aratana Therapeutics had a negative net margin of 33.47% and a negative return on equity of 12.99%. The firm had revenue of $7.36 million during the quarter, compared to analyst estimates of $6.98 million. Sell-side analysts predict that Aratana Therapeutics will post -0.29 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of PETX. Gabelli Funds LLC bought a new stake in Aratana Therapeutics in the 2nd quarter valued at $4,212,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Aratana Therapeutics in the 2nd quarter valued at $2,757,000. SG Americas Securities LLC lifted its position in Aratana Therapeutics by 1,227.7% in the 2nd quarter. SG Americas Securities LLC now owns 392,251 shares of the biopharmaceutical company’s stock valued at $2,024,000 after acquiring an additional 362,708 shares in the last quarter. Millennium Management LLC lifted its position in Aratana Therapeutics by 116.7% in the 4th quarter. Millennium Management LLC now owns 642,923 shares of the biopharmaceutical company’s stock valued at $3,941,000 after acquiring an additional 346,243 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Aratana Therapeutics by 83.7% in the 1st quarter. Acadian Asset Management LLC now owns 439,767 shares of the biopharmaceutical company’s stock valued at $1,583,000 after acquiring an additional 200,379 shares in the last quarter. 65.00% of the stock is currently owned by institutional investors and hedge funds.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

See Also: QQQ ETF

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.